Transgene SA
PAR:TNG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.762
1.48
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Transgene SA
Transgene SA
Accrued Liabilities
Transgene SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Transgene SA
PAR:TNG
|
Accrued Liabilities
€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accrued Liabilities
€41.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accrued Liabilities
€11k
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Accrued Liabilities
€3.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accrued Liabilities
€6.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Accrued Liabilities
€2.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Transgene SA
Glance View
Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
See Also
What is Transgene SA's Accrued Liabilities?
Accrued Liabilities
3m
EUR
Based on the financial report for Sep 30, 2024, Transgene SA's Accrued Liabilities amounts to 3m EUR.
You don't have any saved screeners yet
